Table 1

Demographics and baseline characteristics

CharacteristicsAll patients (n=37)
Age, years, median (range)52 (35–69)
 <6533 (89.2)
 ≥654 (10.8)
ECOG PS
 03 (8.1)
 133 (89.2)
Tumor type
 Ovarian carcinoma33 (89.2)
 Fallopian tube carcinoma4 (10.8)
FIGO stage at first diagnosis
 I2 (5.4)
 II6 (16.2)
 III24 (64.9)
 IV5 (13.5)
Location of metastases
 Lymph node29 (78.4)
 Peritoneum21 (56.8)
 Liver13 (35.1)
 Spleen7 (18.9)
 Abdominal cavity6 (16.2)
 Lung5 (13.5)
Number of lines of prior systemic therapy
 14 (10.8)
 211 (29.7)
 310 (27.0)
 46 (16.2)
 ≥56 (16.2)
Platinum resistant status*
 Primary platinum resistant11 (29.7)
 Secondary platinum resistant15 (40.5)
 Primary platinum refractory11 (29.7)
 Previous bevacizumab use6 (18.2)
Histologic type
 Serous adenocarcinoma
  High‐grade22 (59.5)
  Low-grade1 (2.7)
  Unknown5 (13.5)
 Endometrioid carcinoma1 (2.7)
 Undifferentiated carcinoma1 (2.7)
Other epithelial ovarian cancer
 High-grade adenocarcinoma5 (13.5)
 Adenocarcinoma (not otherwise specified)2 (5.4)
PD-L1 expression †, n (%)
 PD-L1 CPS≥18 (21.6)
 PD-L1 CPS<111 (29.7)
Unknown18 (48.6)

  • Data are n (%) unless otherwise indicated.

  • *Patients were categorized as primary platinum resistance (disease progression occurring ≥2 months and <6 months after completing first-line platinum therapy), secondary platinum resistance (progression ≥6 months after completing first-line platinum-based chemotherapy but <6 months after completing second-line or later-line platinum-based chemotherapy) and primary platinum refractory (progression <2 months or no response during the first-line platinum-based chemotherapy).

  • †Mandatory fresh biopsy or archival tissue for PD-L1 expression was not requested at enrollment.

  • CPS, Combined Positive Score; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; PD-L1, programmed death-ligand 1.